Overview

A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial was to demonstrate the efficacy of a 400 μg dose strength of intranasal fentanyl spray (INFS, Instanyl®) and to evaluate the safety and to establish long term tolerability of treatment with INFS doses of 50, 100, 200 and 400 μg.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Fentanyl